Metronidazole extended-release 750 mg is a particular U.S. oral tablet formulation, not a routine strength option interchangeable with 250 mg or 500 mg immediate-release tablets. The “ER” designation describes a modified-release design that affects how the medicine is used. Official extended-release labeling includes instructions to swallow tablets whole and observe formulation-specific food timing. These differences should be confirmed before dispensing rather than inferred from the higher strength printed on a listing.
The branded Flagyl ER 750 mg presentation has a historical discontinued-marketing context, but a brand's discontinued status does not automatically establish the status or inventory of every generic extended-release label. A currently accessible DailyMed label for 750 mg ER documents the formulation, not universal pharmacy supply. The Flagyl brand history provides wider context; this page is the sole dedicated ER 750 mg product hub within our map.
This guide is intended for readers interpreting a prescription or an ER product listing. It does not encourage anyone to convert an immediate-release regimen, divide extended-release tablets or seek an obsolete brand through unverified sellers. If the prescription concerns ordinary oral tablets rather than ER, start with the standard tablet guide. For legitimate pharmacy fulfillment after the clinician's decision, use the oral buying guide.
An extended-release formulation is engineered to deliver the active ingredient with a different release profile from a conventional immediate-release dosage form. The ER designation is part of the medication's identity. For metronidazole, 750 mg extended-release tablets appear in U.S. labeling with instructions specific to that formulation, so the numeral 750 alone is insufficient to describe the prescribed medicine.
The distinction also affects how a product is listed and checked by pharmacists. An accurate order should include oral tablet, 750 mg and the extended-release designation. A pharmacy listing that omits ER could describe a different medicine or incomplete information and should be clarified before purchase.
| Feature | Metronidazole ER 750 mg | Standard oral tablets |
|---|---|---|
| Release design | Extended-release formulation | Immediate-release formulation |
| Strength examples | 750 mg per ER tablet | 250 mg or 500 mg per tablet |
| Swallowing instructions | Label says do not split, chew or crush | Consult the exact immediate-release label |
| Food instructions | ER label specifies fasting conditions | Check separate tablet instructions |
| Substitution | Requires product-specific professional decision | Not equivalent based on milligrams alone |
The U.S. label for metronidazole ER 750 mg instructs that the tablet should not be split, chewed or crushed. It also states that the product is taken under fasting conditions, a formulation-specific characteristic connected to its release behavior. These are label facts to discuss with a clinician or pharmacist, not an invitation to begin or adjust therapy without a prescription.
If swallowing a whole tablet is difficult, ask a professional about appropriate options. Do not crush an ER tablet or try to reproduce a release profile by taking smaller conventional tablets. Instructions for other metronidazole forms may differ, so an across-the-board rule drawn from an ER label can be misleading.
Flagyl ER was the branded metronidazole extended-release tablet product in the 750 mg strength. The brand is associated with discontinued marketing records, and historical FDA approval documents may remain publicly available. Those historical records should not be interpreted as an offer to supply branded tablets through a pharmacy today.
Generic extended-release labels and FDA product records may require separate assessment. Verify the specific approved product, its current marketing information and whether any licensed pharmacy can fill the prescription. Neither a manufacturer archive nor a web page saying “Flagyl ER” proves immediate availability. The availability guide describes current-product checks rather than conjecture.
Extended-release 750 mg metronidazole tablets have a product-label history connected to bacterial vaginosis, but that does not mean every patient with vaginal symptoms should seek ER tablets. BV diagnosis and treatment choice require evaluation, and current clinical guidelines present multiple treatments with different routes and formulation properties.
In particular, vaginal 0.75% metronidazole gel and an oral 750 mg ER tablet are not competing package sizes of the same medicine. They differ in administration, systemic exposure, labeling and practical prescription requirements. The vaginal product hub focuses on intravaginal options; this ER page remains about the oral modified-release product.
Two or three immediate-release tablets may sum to a nominal milligram amount, but that arithmetic does not reproduce the extended-release design or prove the same treatment exposure. Similarly, dividing or crushing an ER tablet can alter the intended release profile. The prescription must identify the proper formulation and should not be rewritten by the patient or an unverified seller.
A pharmacist may contact the prescriber if ER stock is unavailable or a prescription is ambiguous. Any change depends on the clinical indication, labeling and a new authorized plan, not on a convenience calculation. A product comparison should clarify the question to ask, not propose an improvised regimen.
Confirm the full drug name, extended-release wording, 750 mg strength, oral tablet dosage form, manufacturer or labeler and package details. Consult current FDA approval information and the actual drug label. A distinct NDC or label may help identify a package but does not show what any individual pharmacy presently stocks.
If an order says only “metronidazole 750 mg,” the pharmacy should verify whether extended release is actually intended. An amount of 750 mg can also appear as a prescribed amount in other contexts, which makes product form especially important. Ask the pharmacist rather than guessing from a number in a shopping cart.
Metronidazole ER is a prescription antimicrobial with warnings and precautions. The clinician should review other medicines, relevant health history and the reason treatment is being considered. Product-specific labeling also details interaction and administration concerns, so patients should use the actual dispensed label rather than rely on a general online dose summary.
Seek prompt professional advice for worrying reactions and do not take the product for undiagnosed symptoms or save unused tablets for a new infection. The ER dosage form does not eliminate oral metronidazole's systemic risks. Decisions about appropriateness or an alternative belong to the treating clinician.
A drug database may retain a historical brand entry after commercial marketing changes, and a separate extended-release generic label may appear under the ingredient name alone. Neither entry on its own establishes that a chosen pharmacy can supply the requested product. The safest approach is to match the exact extended-release dosage form, strength and manufacturer or labeler, then ask the pharmacist to confirm the current item and any permitted equivalent.
The distinction between regulatory approval, active marketing and local inventory matters especially for older branded presentations. A seller that promises a discontinued brand without clear product information needs scrutiny. FDA approval records answer questions about drug products; they are not an up-to-date national inventory service or a recommendation to bypass prescription requirements.
A patient who previously received ordinary metronidazole tablets may recognize the ingredient name and inadvertently overlook the letters ER. This is particularly consequential because modified-release tablets have instructions that are not shared automatically by immediate-release products. The pharmacist should explain which formulation has been dispensed, whether the label instructs swallowing whole, and any required separation from meals for that specific ER medicine.
If a refill label appears inconsistent with a prior order, or if a patient cannot follow the ER tablet instructions, the discrepancy should be resolved before using the medicine. A clinician may need to review the formulation choice. This check is about preventing product mix-ups, not encouraging patients to modify dose timing or substitute tablets without direction.
Read the order and dispensing label for “extended release,” 750 mg, oral route, quantity and instructions. Verify that the patient can follow the prescribed administration directions and has a chance to discuss any swallowing problem or medication interaction with the pharmacist. Confirm that the pharmacy is licensed and can identify the actual product it is dispensing.
If the requested brand or generic item cannot be supplied, have the pharmacy coordinate with the prescriber rather than converting the product independently. FDA labeling and historic approval data are reference material; the pharmacy must confirm current stock and permitted substitutions.
It is a prescription oral extended-release metronidazole tablet containing 750 mg of the active drug, with a different release design from ordinary immediate-release tablets.
No. Equal nominal milligrams do not mean the same release profile or an appropriate substitution. Changes require a clinician’s decision and pharmacy verification.
The ER product labeling says not to split, chew or crush them. Discuss swallowing problems with the prescriber or pharmacist.
Yes. Its U.S. label specifies administration under fasting conditions. Confirm the exact instructions on the dispensed prescription.
The branded Flagyl ER presentation has discontinued-marketing history. Do not assume branded inventory from archived FDA labels or promotional listings.
No. Official labeling or approval information does not establish live pharmacy availability. The precise product and current supply must be confirmed with a licensed pharmacy.
Not automatically. The oral ER and vaginal gel formulations differ in route, label and use. A clinician determines what treatment is appropriate.
Yes. Extended-release designation is part of product identity; the pharmacy must match the ordered release type and other prescription details.
Do not treat them as interchangeable. A substitution needs clinician authorization and product-specific review.
Confirm 750 mg, oral extended-release tablet, valid prescription, administration directions, licensed pharmacy and actual availability of the specific item.